People with epilepsy plus learning disabilities pose a challenge in terms of clinical management and research investigation, and, to date, the measurement of outcomes in this population has been limited. There have been uncertainties concerning both the 'what' and the 'how' of assessment. This paper presents a comprehensive review of available outcome measures across nine domains, i.e. relating to seizures, drugs, cognitive function, behaviour, social functioning, carer functioning, attitudes, motivation and 'quality of life'. This last domain reflects more global measures designed to encompass several assessment strands. The uses and limitations of each scale is discussed and, where data are available, psychometric properties are also presented. The paper concludes with suggestions for the further development of outcome measures in this population.
INTRODUCTION
Kerr and Espie' have highlighted the importance of valid and reliable measurement of therapeutic outcomes in people who have epilepsy plus learning disability. This paper has four aims which flow logically from the conceptual base already provided by Kerr and Espie. These can best be stated in the form of questions.
First, what are the domains of measurement which are appropriate to target in this population? Secondly, what measurement criteria, both psychometric and practical, have to be met? Thirdly, are there existing measures, or ones in development or common usage, which fit the bill? Finally, what are the implications for current clinical practice and for priority research development? This paper is based upon a 'round-table discussion' amongst the authors, which took place at a recent major scientific meeting. It represents our pooled knowledge and experience and is intended to provide a position statement on current good practice and future direction.
WHAT SHOULD WE MEASURE AS OUTCOME VARIABLES?
Nine possible domains of measurement arise and are worthy of consideration. These are described in the first column of Table 1 .
Traditionally, the ictus and the immediate pre-and post-ictal period have been the focus of concern in This paper summarizes a round-table discussion which took place at the Second European Congress of Epileptology, The Hague, the Netherlands. in September 1996. The meeting was supported by an unrestricted educational grant from Janssen-Cilag Ltd. PO Box 79, Saunderton, High Wycombe, Buckinghamshire, HP14 4HJ, England, UK.
1059-13111971050337 + 14 $12.00/O @ 1997 British Epilepsy Association the treatment of epilepsy. Often the seizures are the sole focus. The importance of the clinical history, of diagnostic evaluation, and of ongoing monitoring of seizure events is self-evident in epilepsy work. However, in this particular population accurate identification, differential diagnosis and reliable recording of seizure frequency can prove very problematic. Furthermore, the patient is often unable, due to intellectual and/or communication difficulties, to describe their symptoms and clinicians have to rely on carer observation and report (see Espie and Paul2 for a review).
A second area for measurement relates to antiepileptic drugs (AEDs). Treatment with AEDs is the mainstay of clinical practice. It is generally the effectiveness of these drugs which is being evaiuated in the clinic. Concerns about compliance and about frequency of side-effects often arise, and these have to be quantified and weighed in balance against evidence of benefit. Importantly, other drugs may affect seizure thresholds, and the genera1 functioning of the individual. Prescription of neuroleptic medication, for example, in people with learning disabilities, is not uncommon3.
Allied to monitoring drug side-effects, in particular that of drowsiness, is the appraisal of cognitivefunctions. There is a long history of neuropsychological expertise associated with both research and practice in epilepsy (see, for example, Bennett4). It is important to recognize that neuropsychological functions may be affected directly by seizure activity, by drug effects (as mentioned) by variation in arousal state', by environmental conditions2, by circadian factors (Espie et al in press), and possibly also by care practices.
There is some literature on the association between behaviourlpsychopathology and epilepsy in people with learning disabi1ities2y"t'.
The 'epilepsy plus' presentation is often comp1ex'2 and an understanding of the interrelationships between various clinical concerns may be critical to effective management. Non-epileptic seizures and self-induced seizures are relatively common in people with learning disabilities, and in most cases occur in people who also have genuine epileptic attacks'.
Although epilepsy can be regarded as a symptqmatic disorder, or even as purely a symptom of an underlying neurological disturbance, nevertheless, it is often associated with considerable impact upon socialfunctioning. In people with learning disabilities constraints upon independence and skill development are, of course, inevitable by virtue of the individual's condition. However, there is some evidence of additional handicapping where epilepsy presents as a co-morbid problem lo* I'. For example, the presentation of epilepsy may become a barrier to community placement. The genera1 literature on epilepsy attests the impact of a diagnosis of epilepsy upon employment and leisure opportunityt3.
The majority of people with learning disabilities have family or staff carers who are intimately involved with their lives. Curer functioning, therefore, becomes a concern. The clinician normally works through the carer and will often recognize that epilepsy is a family prob1em14. The carer's ability to sustain the care role is crucial to the patient's wellbeing, and yet it may be difficult for carers to achieve a healthy balance between responsibility and independence. Carers do experience strain, and family carers in particular may be prone to experience clinically significant levels of anxiety and depression15.
A considerable amount is known about attitudes which people (both sufferers and society) have towards epilepsy. In particular, social stigma has been researched16s17 and attributional states may make an important contribution towards coping with epilepsy . '& I9 In the field of learning disabilities, people's level of knowledge about the condition and their views and values have not, to our knowledge, been formally reported. Nevertheless, this seems an important area for development.
Similarly, motivation has received scant attention in spite of the fact that factors such as regular attendance at clinics and compliance in taking medication may be critical to achieve optimaI con& over seizures. In learning disabilities, we are of course concerned also with the motivation and compliance of carers, and this would seem to be an appropriate domain for measures to be developed. Treatment compliance is regarded as a critical ingredient in good therapeutic outcome20.
Finally, there has been considerable interest in recent years in 'qualiry of fife'. This is included as a separate category, primarily in recognition of the fact that some measures attempt to span a number of the domains mentioned above. Thus, we may regard quality of life as a construct which reflects a number of facets of well-being. There are some published scales for measuring quality of life"-23; however, it is only in recent times that specific attention has been paid to quality-of-life assessment in the population of people who have epilepsy and learning disabilitiesr5.
WHAT MEASUREMENT CRITERIA SHOULD BE APPLIED?
It is nut the purpose of this paper to review in any detail psychometric properties of scales, However, it may be helpful to describe the key qualities which measurement instruments should demonstrate. These are validity, reliability, sensitivity and practicability.
Validity is the most important property since it relates to the question: Are we measuring what we think we're measuring? However reliable, sensitive and user-friendly a scale may be. if it is not valid for the purpose of which it is intended, it is of no value at all. Validity places the emphasis on whar is being measured and in particular, whether the instrument is measuring what the investigator intends it to measure. Most classification systems describe four types of validity, i.e. content validity, criterion-related validity, construct validity and face validity. Content validity refers to the representativeness or sampling adequacy of the content of the measuring instrument. A scale should comprise items which can be judged as representative of its purpose. Criterion-related validity is where a scale is compared with external variables (criteria) which are known to measure the attribute under study. The higher the correlation between the scale and the criterion, the better the validity. Construct validity relates to the meaning of the test. In other words it is more preoccupied with theoretical constructs. Construct validation is not simply a question of validating a test but of validating a theory behind a test. Finally face validity, as the term implies, relates to the instrument 'looking right' to potential users. Its purposes and uses should be explicit and overtly obvious.
Reliability has synonyms such as dependability, stability, consistency, predictabiIity and accuracy. Measures are more or less variable from occasion to occasion and in this sense are either stable, and relatively predictable, or they are unstable, and relative unpredictable; they are consistent or not consistent. If they are reliable we can depend upon them and if they are unreliable we cannot. Typical questions about reliability are: If we use this instrument again will we get the same or similar results? How much measurement error is there in the scale? Test-retest reliability is when the same scale is administered on two separate occasions. Interrater reliability is used to check reliabiiity of scores across observers. Internal consistency is a way of estimating reliability from the variances and covariances of all the items with each other. An extension of internal consistency is item deletion which systematically assesses the stability of a scale with items removed.
In addition to validity and reliability, a measure should demonstrate sensirivify; that is it should be capable of discriminating, in a consistent manner, between individuals, say with different levels of symptomatology, and within the individual to detect change over time, say in response to treatment. If a measure is not sensitive it may fail to detect genuine improvement or deterioration. Clearly it is desirable that a scale should be sensitive. However, there can be problems where only two measurements are taken, e.g. before and after treatment, since a sensitive measure may be quite reactive to particular circumstances, such as the day on which it was completed. Multiple assessments of change can be useful with several values taken in both baseline and treatment phases. Also immediate/marked change after intervention tends to most reliably indicate the efficacy of the treatment.
Finally, it is critically important that any measure used is practicable. It would be possible to devise measures and procedures which are sophisticated in psychometric terms but which are simply too complicated for people to administer or which take up too much time in practice. It is essential to take into account the genuine constraints of the setting in which measurements take place. These include the time required for each assessment, the numbers of people to be assessed, the effects of fatigue, the readability of the scales and the compliance both of staff and of patients and their carers with the procedures.
WHAT OUTCOME MEASURES ARE CURRENTLY AVAILABLE?
Having considered the domains of measurement and the criteria which should be applied to specific assessments, this section will now review the range of outcome measures in current use. These are summarized in Table 1 , where information on scale 'qualities' is also presented.
Measures relating to seizures
The International League Against Epilepsy (ILAE) classification is accepted as the standard system of classification and terminology24. Nevertheless, there are recognized difficulties in interobserver agreement, even when standard criteria are applied2vZ5. Clinicians very seldom observe seizures at first hand and generally have to rely on a verbal or a written report. The Concerted Action Family Data protocol is a document produced for a Europe-wide project on the genetics of epilepsy. It seeks to provide clear written recordings of actual seizures and investigations for the individual and other family members (F. Elmsley, pers. comm.). These can be coded against the ILAE classification and confidence in reaching the diagnostic decision can be measured on a scale of l-5. There may be advantages to this approach over the traditional use of seizure charts, which are widely produced by clinical departments and by the pharmaceutical industry. Such charts have the advantage of being very quick to complete and to give 'a week at a glance' overview. However, they may commit inexperienced observers to differentiate between seizure types, a distinction which is known to be difficult, even amongst experienced clinicians. Furthermore, some charts refer to 'major' and 'minor' fits; a rather arbitrary dichotomy. A considerable problem for most recording systems is that certain types of fits, e.g. absence seizures and myoclonic seizures are difficult to detect and their true frequency difficult to record. Repeated absence seizures can be usefully assessed by continuous monitoring (e.g. the St. Piers, Lingfield Monolog Monitor). Pau126 and Espie and Paul2 describe the use of seizure diaries which have a similar philosophy to the Concerted Action Protocol. Behavioural descriptors are written for each of the common seizure presentations exhibited by an individual which then requires carers only to enter a code letter and time at each presentation of the seizure, rather than having to make a classification decision. The seizure diaries can then be presented to clinicians and are more likely to provide the critical information required for diagnostic and treatment purposes. Behavioural descriptors can be improved by interviewing several eye witnesses in order to agree criterion features.
Direct observation/recording of seizures is, of course, technically possible, e.g. video telemetry, observer data on hand-held computers'. However, seizure events often prove elusive. For example, Espie and Paul2 captured only 11 events in 1388 random videotape samples of 28 people with refractory epilepsy. Betts advocates the use of video-recording by means of a video-camera lending system to maximize this assessment processzs. Video records are particularly helpful in the differential diagnosis of epileptic and non-epileptic seizures. Behaviour analytical methods are also widely used to identify antecedent triggers for seizures, to establish contexts/times when they are most likely to occur and to determine the effects of the seizures within the environment in which they occur. Such analyses can be readily incorporated into seizure -diaries. Clearly it is valuable to have as much descriptive information as possible on seizure presentation since this can permit a broader approach to intervention.
The Liverpool Seizure Severity Scale (LSSS)2' was originally designed for self-completion by adults in AED trials. It has recently been adapted for completion by carers of children with learning disabilities and has been used in a randomized clinical trial of a novel AED in the treatment of Lennox-Gastaut Syndrome. The LSSS appears to have good validity and reliability. Apart from a recently published paper by Carpay eta1 , 27 this is probably the only severity scale which would be of value with this particular patient population. To our knowledge, the Chalfont Seizure Severity Scale has not been adapted for use with learning disabilities. Seizure severity is, of course, a difficult concept to define. In the LSSS, severity is measured principally in relation to the ictal and postictal effects of the seizures. It must be recognized that a physician, carer, and a patient may have different views concerning the severity of the patient's pattern of seizures. Each perspective is valid and may be valuable. Similarly, the extent to which seizures are intrusive upon lifestyle crucially depends upon that lifestyle. For example, one seizure per month experienced by someone who is working may be extremely disruptive, and an individual with seizures every day may adapt to this expectation.
Measures relating to drugs
People with learning disabilities may not be able to tell clinicians about side-effects experienced while taking a drug. Also, it may be difficult to differentiate between the effects of a particular drug and symptoms which have already been there for quite some time. Attention to the history is important before conclud-ing how to attribute them. There is a natural tendency to wish to find explanations of symptoms. Nevertheless, it is important to do so with some accuracy of prediction. There is also the difficulty of distinguishing drug effects from epilepsy effects and this is usually dependent upon a judgement made by the person completing the scale, or conducting the interview. Discontinuing medications can also be problematicZ8 and may confound measurement.
Drug profiles normally include lists of known sideeffects, and these can provide a reasonable check list on events which may be predictable. Although there may be a risk of putting words into people's mouths, with this patient group it is very important to be proactive in seeking information due to inherent communication problems. Much may depend on the relationship of the carer to the person with learning disabilities, how long they have known the individual, and the consistency with which they attend the clinic. Some doctors also find that circulated lists produced by pharmacists can be very helpful. The majority of AEDs have recognized specific side-effects (e.g. Lamotrigine rash) rather than there being a core data set which would apply to all AEDs. Some symptomatic side-effects are clearly visible whereas others, such as double vision, are experiential and rely entirely upon self-report. It is the experiential sideeffects which are less likely to be detected in the learning disability population. The development of materials like 'widget symbols'* may in time permit greater free responding for people with communication difficulties.
Behaviour change, observable to a familiar carer, may also be an indication of drug effects"*'9*30. Some of these changes can be quite subtle. Furthermore, symptoms of somnolence and passivity may be more readily accepted as tolerable by carers than symptoms of irritability and upset. This is a concern since there may be marked interruption of functioning in such cases. Table 1 mentions several scales, produced by the pharmaceutical industry which help to monitor signs and symptoms. The Adverse Events Profile3t has been developed as a patient-perceived side-effects profile and has recently been adapted for completion by a parent or carer.
There are objective tests, developed within experimental paradigms, for measuring vigilance and attention; which is a marker for a person's ability to process information. In one major study, the Leeds Psychomotor Test was adapted to a very simple twochoice reaction-time test, where subjects had to press a large button pad to extinguish a signal light (Espie et al unpubl.) . A number of departments use such psychomotor tests to monitor drowsiness in people with epilepsy who are on AEDs. However, many of the available test formats are too complicated for people with learning disabilities.
Measures of cognitive function
As Table 1 indicates, there are many published and widely used neuropsychological tests with good psychometric properties, e.g. the Wechsler Adult Intelligence Scale-Revised (WAIS-R)32, the Wechsler Memory Scale-Revised (WMS-R)33, the Rivermead Behavioural Memory Test (RBMT)34 and the British Ability Scales (BAS) 35 However, the majority of . these have not been standardized on people with learning disabilities and will prove insensitive to measurement at the lower end of their scales. The Wechsler scales are amongst the most commonly used in departments. Some tests used to illustrate the effect of sub-clinical epileptic discharges in right and left hemisphere tasks have been computerized and are operated by the use of a touch-sensitive screen. An example of such a test is derived from the Corsi block test36. The test, time-linked to EEG, allows comment on the location of an epileptic focus in cases where this cannot be detected by more standard procedures3'. The FePsy38 is another computerized battery of cognitive function tests comprising sub-tests on vigilance, reaction time and psychomotor function. Extensive normative datasets are available for the FePsy, including some data from children with special educational needs. However, both the Corsi tests and the FePsy are probably best restricted to more able groups of people within the population of those with learning disabilities.
A neurotoxicity scale to assess the effects of cognitive functioning on daily activities has been developed . 39.40 Simple analogue ratings where target functions such as 'concentration' or 'tiredness' are scored along 10 cm lines can act as a gauge of perceived function. Such measures have the advantage of being completed very quickly, and have face validity but at present lack any other formal psychometric justification.
Behavioural state analysis4'*42 is a system which ascribes arousal status to observed behaviour. The optimal state of 'awake-active-alert' implies that the individual is actively engaged with his/her environment. Criteria have been drawn up for this and other behaviour states, e.g. awake-inactive-alert, drowsy, dazed, sleep. However, there is some debate in the literature as to the reliability of such measurement43. These studies have not been conducted specifically on people with epilepsy; however, Espie er al have done so recently (Espie et al unpubl.). The principal prob-*Widget Software, 102 Radford Road, Leamington Spa CV31 ILS. lem with behaviour-state analysis is that it requires trained observers to observe individuals over lengthy time periods. It is more an education and training methodology than one for treatment-outcome practice.
Measures of behavioural adjustment
A number of useful measures of behaviour and psychopathology are reported in Table 1 . The Psychopathology Inventory for Mentally Retarded Adults (PIMRA)85 may be used as a structured interview to identify formal psychiatric disorders in people with learning disabilities. The PIMRA has been available for some years. More recently the Psychiatric Assessment Schedule for Adults with Developmental Disability (PASSAD) has become the 'gold standard' and is sometimes used in clinical trials as a screening measure, particularly to identify psychosis (Hester Adrian Research Centre, Manchester, 1994) . More commonly, however, clinicians are interested in types of behavioural disorder and their severity. The Aberrant Behaviour Checklist (ABC)45 may be particularly appropriate for use with people who have learning disabilities plus epilepsy since it was originally developed as an outcome measure for use in clinical trials. Similarly, the Psychosocial Behaviour Scale (PBS)46 was designed specifically for people with learning disabilities and epilepsy, particularly for more able individuals who present antisocial and attention-seeking behaviours. Both the ABC and the PBS have useful sub-scales and have published validity and reliability data. The Adaptive Behavior Scales-Part Two4' are commonly used in clinical practice and are useful, although they do not specifically relate to this co-morbid patient group. They can also be time-consuming to complete. Other measures include the Attention Deficit Disorder-Hyperactivity Questionnaire on which Espie and Paul have some unpublished data (translated from Boudreault et a148) and O'Brien's SSBP postal questionnaires which are suitable for both children and adults and incorporates developmental assessment49y50. Recent extensive reviews of published behavioural measures can be consulted for further information5 l.
A new scale has been developed for use in a trial of patients with Lennox-Gastaut Syndrome55. The starting point for the Epilepsy and Learning Disability Quality of Life Scale was a compilation of anecdotal information from experienced clinicians. The scale is completed by parents and has been used in a major European drug trial comprising 140 patients. It has 66 items comprising three sub-scales on seizure severity (adapted from the Liverpool adult version), behaviour (sleep, appetite, communication, alertness) and mood (irritability, cheerfulness etc.). The scale has been validated both by clinicians and carers and reliability data are satisfactory. Test-retest reliability on the mood sub-scale was not strong, but this is not surprising since mood does fluctuate more than behavioural variables (see also later section on 'global measures').
It is important to recognize that in clinical practice many people do not use scales. They are too time-consuming either in administration or in terms of productive use of the data which they generate. Nevertheless, behavioural information should be appraised, particularly where specific problems are reported within the individual presentation. For clinical practice, Kerr recommends a simple visual analogue scale where up to five targets which drugs and the treatment of epilepsy might affect are agreed between carers and the clinician. Changes in these related to an agreed baseline can then be assessed. This approach represents the ultimate in validity for individual clinical work although it is not possible to collate data across subjects using this method. In practice, many clinicians have their own local measures for monitoring behavioural factors and some use measures which are supplied by the pharmaceutical industry.
One of the difficulties in working with people with learning disabilities is the assessment of temperament and mood independently from behaviour. Nevertheless, it does seem important to recognize underlying mood states and personality characteristics which may have a bearing upon presentation. The Psychosocial Behaviour Scale46 measures aspects of trait tendency, e.g. attention-seeking behaviour. The Zung Anxiety Scale has been adapted for use with people with mild learning disabilities56.
Measures relating to social functioning
The best-known scale in this domain is the Washington Psychosocial Seizure Inventory (WPSD5'. However, the WPSI loads very heavily on independent social functions such as employment, driving, income, etc. and has limited validity, therefore, except for those people with mild/borderline learning disabilities. It also has a North American emphasis and psychometric limitations in that its scaling is generally in yes/no format which does not permit gauging of strength of emphasis. There is no means by which more important areas can be differentially weighted. Clark makes use of the WPSI-Professional Rating Scale which is a professionally completed short version, but again only for more able patients.
The Vineland Adaptive Behaviour Scales (VABS)58 can be recommended as a robust, descriptive measure ule6* may be useful in assessing parental concerns in children with epilepsy. of social functioning. In particular, the expanded form of the VABS sub-scales on personal, daily living and community skills can be used for detailed descriptive purposes. They are less useful as outcome measurements because of their global nature.
Other measures of social functioning include the Adaptive Behavior Scales-Part Two4' and the Lidcombe Psychosocial Disability Scale59. The former is extensively used in North America and provides a comprehensive profile of personal and daily life functions, and the latter is Australian and is a brief assessment of social functioning for use with patients who have acquired brain damage.
Once again, the most suitable measure will depend upon the measurement purpose. In research studies a standardized scale may be required to look at psychosocial outcome over the longer term. In clinical trials, which may last only relatively short periods of time, it is unlikely that global social functioning will demonstrate change. In these circumstances, and in routine clinical practice, more sensitive, specific measures may need to be devised to reflect the particular goals of the intervention and the individual's particular circumstances. Some departments incorporate an index of social functioning within the interview process (e.g. O'Brien: Clinical History Questionnaire), also some syndrome-specific measures may be developed which are sensitive to the specific social and functional sequelae of individual disorders (e.g. Rett Disorder6').
Measures relating to attitudes
There is a sizeable literature on concepts such as stigma. However, little is known about how the person with learning disabilities feels, and is perceived by others, when they have epilepsy. Similarly, little is known about their knowledge and understanding of epilepsy itself. The Epilepsy Knowledge Profile (EKP)69 represent a recent attempt to develop measures in this latter area for people with epilepsy. More recently, the EKP (Personal Information) has been adapted for direct use with people with learning disabilities'O and the EKP (General Knowledge) has been used with carers of people with learning disabilities to assess their knowledge of the condition (Espie et al in press).
Clearly, further work would be welcome in this field since attitudes can be powerful facilitators or inhibitors of therapeutic progress both directly (e.g. compliance with advice) and indirectly (e.g. perceived stigma). Also, mention was made earlier of attributional factors being important in the appraisal of what may (or may not) be side-effects of medication. Similar attributional issues arise in the perceived associations between behaviour and seizures.
Measures relating to motivation Measures relating to carer functioning Reference was made earlier to the fact that epilepsy in learning disabilities affects the family and/or the care system. The capacity of carers to cope is a very important factor in clinical management of the individual with epilepsy. Symptomatic rating scales of anxiety and depression can be useful here, e.g. The Hospital Anxiety and Depression Scale (HADS)61, the Beck Depression Inventory (BDI)@, and the General Health Questionnaire (GHQ)63. The Index of Psychological Well-being& can also be recommended as a very brief scale.
Rather than assessing carer symptomatology, another approach is to measure the carer's experience of strain and responsibility. Clark recommends the use of a Family Feelings Questionnaire which is a local modification of the Burden Inventory65. The concept of burden can be subdivided into objective burden and subjective burde#. The Caregiver Strain Index6' was originally developed for carers of people who had experienced a CVA. It has the advantage of being relatively brief and may be readily adapted for this carer group. The Impact of Epilepsy SchedAll clinicians utilize some implicit measure of the individual's or the carer's motivation. These might be default patterns from attendance at clinics, compliance with advice in taking AEDs, etc. Everyone would agree that motivation is a crucial issue. Nevertheless, there are few measures of the concept. The results of clinical trials of AEDs inevitably represent the optimal situation. That is where subjects have remained in the study, have complied with the sometimes rigorous schedule of repeated measurement and attendance at clinics, and have taken drugs in prescribed doses. The extent to which such results generalize to the more heterogeneous clinical population is not guaranteed. Clearly, effort should be made to record motivation in some form and behavioural measures such as attendance rates may be the most robust.
Motivation may be measured in a more indirect way through scales such as the Rosenbaum Selfcontrol Schedule (RSCS)". Although this is a complex measure, which takes some time to complete, a shortened version has been developed comprising only six items '* The RSCS measures the individ-. ual's tendency to internalize or externalize the locus of control. In other words it is a measure of personal resourcefulness. This could be a useful measure for more able patients or for carers. There is some evidence that people with learning disabilities and epilepsy have an external locus of control orientation' ' . The Adolescent Coping Scale73 may also be useful with younger people for similar purposes.
Global assessment measures (quality of life)
There will always be tension between detailed, specific measurement and measures which seek to take a global overview. The decision about which path to go down will be a pragmatic one, situationally determined and heavily influenced by the amount of time available. Formal research studies will generally afford the opportunity for multiple measurements whereas clinical practice will be heavily timeconstrained. Nevertheless, global measures will also be useful in research study since an integrated measure may give a better picture of the variance within and between subjects, and reflect a true-life picture. This section of Table 1 , therefore, summarizes those measures which could be considered global and reflective of the concept of 'quality of life'. The new scale for children with learning disabilities and epilepsy (ELDQOL)76 has already been discussed, and appears to meet the criteria for global measurement. The Liverpool group have previously published quality-of-life assessment scales which are in widespread use in research and clinical practice74. These measures incorporate the LSSS mentioned earlier but also include assessment of the impact of epilepsy-adults and children75v76* life fulfilment77; stigma54; and AED side-effects (Baker, unpubl.) .
The Epilepsy Outcome Scale (EOS) (Espie et al in press) is another new scale which has been developed specifically for use with adults with epilepsy and learning disabilities. This scale was derived from workshops held with family and staff carers of people with learning disabilities. Through an iterative process, items were selected which reflected their principal concerns in four main areas, i.e. concerns about seizures, drugs, injury and effects on day-to-day living. The EOS has been well validated and has very good psychometric properties making it potentially useful as a research tool. It also has the advantage of being quickly completed and being suitable for use in clinics. Further studies are underway to consider its sensitivity to measure change.
A Health of the Nation Outcome Scale (HoNOS) specifically for use with people who have learning disabilities is currently being developed by a working group under the aegis of the Department of Health. This would be primarily for surveying and comparing large populations on clinical and social characteristics. It is not yet clear what content the HoNOS scale would have, although it is likely to be relatively brief and suitable for completion by any professional involved in care provision. It is to be hoped that epilepsy will be included as one dimension of outcome measurement.
WHAT ARE THE CURRENT PRIORITIES FOR RESEARCH AND DEVELOPMENT?
The authors would suggest five major priorities. First, it is clear from the review that relatively few scales have been adequately tested on people with learning disabilities. The review identifies the extent to which available measures can be validly and reliably applied. Assumptions cannot be made concerning the psychometric properties of scales and their applicability to 'new' populations. The first priority, therefore, is for good-quality research on scale development to continue. A number of promising scales are emerging, for example, as global measures (Epilepsy Outcome Scale; Espie et al in press; ELDQOL7*). Also it will be critically important to demonstrate, through scientific study, that measures are capable of picking up real changes at follow-up.
Secondly, measurement within learning disability is often more indirect than within general clinical practice. Carers' needs and concerns are likely to influence the reporting of outcomes, and these may differ depending upon which carer you ask. It will be important to develop methodologies for comparing and correlating perceptions and perspectives on the patient's epilepsy. Also, measurement of carer 'coping' may yield an important predictor variable. Furthermore, the patient's own viewpoint should not be omitted by default. It may be more accessible than is generally thought.
Thirdly, there are particular problems associated with the measurement of cognitive functioning in people with learning disabilities. Few neuropsychological and psychomotor batteries have norms which extend into the range of even moderate learning disability. Thus, there are 'floor effects' in measurement which severely curtail their applicability. Objective measures of attention and vigilance probably offer the most fruitful line for development here. Learning disability is generally defined in terms of both intellectual and social handicap. Scales for the appraisal of the latter appear more robust.
Fourthly, there is still a considerable amount of work needing to be done on differential diagnosis in this population. Both neurophysiological and structured behavioural data may be required to ascertain the clinical diagnosis with any reliability. Videotape evidence, real-time recording and ambulatory monitoring should be further studied. The reliance on clinical judgement, albeit based on the comments of experienced (but untrained) observers, is less than satisfactory. This is particularly the case given that patient self-report is usually a critical component of the interview in the epilepsy clinic, and this may be unavailable to aid the clinician's judgement. The ideal model is that of the 'scientist-practitioner ' where hypotheses are raised and tested through the systematic collection of data relevant to a series of clinical questions.
Finally, and related to the previous point, is the importance of developing methodologies for the assessment of 'dual therapies', i.e. pharmacotherapy plus psychological therapy. The high prevalence rate of non-epileptic seizures and of self-induced seizures in this population has clear implications for such a methodology.
